艾迪藥業(688488.SH):擬向銀行申請不超0.8億元的綜合授信額度
格隆匯3月14日丨艾迪藥業(688488.SH)公佈,為滿足公司經營和業務發展需要,公司擬以信用方式向寧波銀行股份有限公司南京分行申請總額不超過人民幣0.8億元的綜合授信額度,授信產品包括但不限於流動資金貸款、銀行承兑匯票、保函、信用證等。公司向銀行申請的授信額度最終以銀行實際審批的金額為準,授信期限為1年,授信期限內授信額度可循環使用,具體融資金額在綜合授信額度內根據公司實際資金需求情況來確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.